Creating Cancer Institute Strasbourg Europe Trials

From Beacon

Warning: You are recreating a page that was previously deleted.

You should consider whether it is appropriate to continue editing this page. The deletion and move log for this page are provided here for convenience:

  • 17:54, 22 June 2024 Victor talk contribs deleted page Cancer Institute Strasbourg Europe Trials (content was: "'''NCTID''': NCT04717414 '''Title''': An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions '''Study Summary''': The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compa...", and the only contributor was "Woloski" (talk))
Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to your username, along with other benefits.
Please note that all contributions to Beacon may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see Beacon:Copyrights for details). Do not submit copyrighted work without permission!
Cancel Editing help (opens in new window)